CardioDx Inc. gained five new investors in a $60 million equity financing round that the Palo Alto company will use to expand reimbursement coverage for its blood test for obstructive coronary artery disease.
CardioDx also will use the money to develop more gene expression tests for cardiovascular problems.
No comments:
Post a Comment